Showing results (251-260 of 346) with videos related to
Sort By:
Pageof 35
The Journal of Antimicrobial Chemotherapy|August 12, 2021
Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumoniaTakayuki Katsube, David P Nicolau, Keith A Rodvold, et al.Antimicrobial Agents and Chemotherapy|May 23, 2018
Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult SubjectsKeith A Rodvold, Mark H Gotfried, Rakesh Chugh, et al.Antimicrobial Agents and Chemotherapy|June 13, 2018
Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult ParticipantsEric Wenzler, Susan C Bleasdale, Monica Sikka, et al.Critical Care Medicine|August 18, 2006
Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. databaseAndrew F Shorr, Ying P Tabak, Aaron D Killian, et al.Congestive Heart Failure (Greenwich, Conn.)|January 29, 2011
Burden of sodium abnormalities in patients hospitalized for heart failureAndrew F Shorr, Ying P Tabak, Richard S Johannes, et al.American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|November 9, 2007
Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgeryAndrew F Shorr, Matt W Sarnes, Patricia J Peeples, et al.Critical Care (London, England)|October 27, 2011
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasisDaniel H Kett, Andrew F Shorr, Annette C Reboli, et al.Critical Care Medicine|March 1, 2006
Critical care delivery in the United States: distribution of services and compliance with Leapfrog recommendationsDerek C Angus, Andrew F Shorr, Alan White, et al.Plos One|June 24, 2025
Ceftobiprole versus ceftriaxone ± linezolid in Community-Acquired Bacterial Pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidanceAndrew F Shorr, Mark E Jones, Silke Friedmann, et al.Journal of Medical Economics|March 10, 2016
Hospital resource use of patients receiving isavuconazole vs voriconazole for invasive mold infections in the phase III SECURE trialDavid Horn, Debra Goff, Nikhil Khandelwal, et al.Pageof 35